KCT0007647尚未招募未知
An open-label, single-arm, multicenter, phase II study of acalabrutinib and rituximab in patients with mentle cell lymphoma (MCL)
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 60(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. Age =60 years
- •2. Pathologically confirmed MCL (according to the 2016 WHO classification), with documentation of monoclonal B cells that have a chromosome translocation t(11;14)(q13;q32) and/or overexpress cyclin D1
- •3. Stage II-IV, measurable by imaging and requiring treatment in the opinion of the treating clinician
- •4. No previous treatment for MCL (other than localised radiotherapy or 7-day pulse of steroids for symptom control)
- •5. ECOG performance status 0 - 2
- •6. Absolute neutrophil count (ANC) > 1.0 x 109 and platelet count >100 x 109, unless related to lymphoma - in this situation, the threshold for inclusion is ANC > 0.5 x 109 and platelet count > 50 x 109
- •7. Creatinine clearance > 30 ml/min (Cockcroft-Gault)
- •8. AST and/or ALT <3xULN and/or total bilirubin <3xULN
- •9. Able to give voluntary written informed consent
- •10. Woman of childbearing potential (WOCBP) who are sexually active must use highly effective methods of contraception during treatment and for 2 days after the last dose of acalabrutinib or for 12 months after last dose of rituximab, whichever is longer
排除标准
- •1. Patients considered fit enough to undergo autologous or allogeneic stem cell transplant for MCL
- •2. Major surgery within two weeks prior to day 1 of cycle 1
- •3. Patients who are unable to swallow capsules, or who have disease significantly affecting gastrointestinal function that would limit oral absorption of medication
- •4. Known serological positivity for HBV, HCV, HIV. Patients who are hepatitis B core antibody (anti-HBc) positive and who are surface antigen negative will need to have a negative polymerase chain reaction (PCR) result. Those who are hepatitis B surface antigen (HbsAg) positive or hepatitis B PCR positive will be excluded. Patients who are hepatitis C antibody positive will need to have a negative PCR result. Those who are hepatitis C PCR positive will be excluded
- •5. Diagnosed with or treated for any other malignancy than MCL within 2 years prior to day 1 of cycle 1 (except basal cell carcinoma, cutaneous squamous cell carcinoma or any other in situ malignancy)
- •6. Active infection requiring treatment
- •7. Serious medical or psychiatric illness likely to interfere with participation in this clinical study
- •8. Concurrent treatment with another investigational agent outside of this protocol
- •9. Known history of drug-specific hypersensitivity or anaphylaxis to rituximab or acalabrutinib (including active product or excipient components).
- •10. Active bleeding, history of bleeding diathesis (eg, hemophilia or von Willebrand disease)
- •11. Uncontrolled AIHA (autoimmune hemolytic anemia) or ITP (idiopathic thrombocytopenic purpura)
- •12. The use of strong CYP3A inhibitors within 1 week or strong CYP3A inducers within 3 weeks of the first dose of study drug is prohibited
- •13. Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon) within 7 days of first dose of study drug
- •14. Prothrombin time/INR or aPTT (in the absence of Lupus anticoagulant) > 2x ULN
- •15. Requires treatment with proton pump inhibitors (eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Patients receiving proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study
- •16. History of significant cerebrovascular disease or event, including stroke or intracranial hemorrhage, within 6 months before the first dose of study drug
- •17. Breastfeeding or pregnant women
- •18. Concurrent participation in another therapeutic clinical trial
- •19. History of or ongoing confirmed progressive multifocal leukoencephalopathy (PML)
- •20. Significant cardiovascular disease such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification at Screening. Note: Subjects with controlled, asymptomatic atrial fibrillation are allowed to enroll on study
- •21. Received a live virus vaccination within 28 days of first dose of study drug
研究者
相似试验
进行中（未招募）
不适用
?A phase II study to evaluate the efficacy and safety of the investigational compound AUY922 in combination with trastuzumab as second-line treatment in patients with HER2-positive advanced gastric cancerPatients with documented advanced HER2 positive gastric cancer progressing after clinical benefit to 1st line treatment with trastuzumab containing treatment. Clinical benefit is defined as overall response or stable disease of at least 12 weeks, from start of the 1st line therapy with trastuzumab as per RECIST.MedDRA version: 14.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002570-23-ITOVARTIS FARMA48
进行中（未招募）
不适用
A phase II study to evaluate the efficacy and safety of the investigational compound AUY922 in combination with trastuzumab as second-line treatment in patients with HER2-positive advanced gastric cancerPatients with documented advanced HER2 positive gastric cancer progressing after clinical benefit to 1st line treatment with trastuzumab containing treatment. Clinical benefit is defined as overall response or stable disease of at least 12 weeks, from start of the 1st line therapy with trastuzumab as per RECIST.MedDRA version: 14.1Level: LLTClassification code 10066896Term: HER-2 positive gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002570-23-DEovartis Pharma Services AG48
进行中（未招募）
1 期
A phase II study to evaluate the efficacy and safety of the investigational compound AUY922 in combination with trastuzumab as second-line treatment in patients with HER2-positive advanced gastric cancerPatients with documented advanced HER2 positive gastric cancer progressing after clinical benefit to 1st line treatment with trastuzumab containing treatment. Clinical benefit is defined as overall response or stable disease of at least 12 weeks, from start of the 1st line therapy with trastuzumab as per RECIST.MedDRA version: 14.0Level: LLTClassification code 10066896Term: HER-2 positive gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002570-23-BEovartis Pharma Services AG48
进行中（未招募）
不适用
An open-label, single-arm, multicentre, Phase II study of oral lapatinib in combination with paclitaxel as first-line treatment for ErbB2-amplified metastatic breast cancer patients - Phase II study of paclitaxel plus lapatinib in patients with ErbB2-amplified metastatic breast canceMetastatic breast cancerEUCTR2005-003945-16-LVGlaxoSmithKline R&D Ltd56
进行中（未招募）
不适用
Este estudio abierto evaluará la eficacia y seguridad de vemurafenib (RO5185426) en pacientes con melanoma metastásico con metástasis cerebrales tratadas o no tratadas. Los pacientes recibirán vemurafenib (RO5185426) oralmente a una dosis de 960 mg dos veces al día hasta progresión de la enfermedad o toxicidad inaceptable.Metastatic Melanoma with Brain MetastasesMedDRA version: 14.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000954-46-ESF. Hoffmann-La Roche Ltd.132